Equities analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to announce ($0.63) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Stemline Therapeutics’ earnings. The lowest EPS estimate is ($0.66) and the highest is ($0.61). Stemline Therapeutics posted earnings per share of ($0.66) during the same quarter last year, which suggests a positive year over year growth rate of 4.5%. The company is scheduled to issue its next earnings results on Tuesday, August 14th.
On average, analysts expect that Stemline Therapeutics will report full-year earnings of ($2.73) per share for the current fiscal year, with EPS estimates ranging from ($2.91) to ($2.52). For the next year, analysts anticipate that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($2.57) to $1.54. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Stemline Therapeutics.
Get Stemline Therapeutics alerts:Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.02.
STML has been the topic of a number of recent analyst reports. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Thursday, May 10th. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 10th. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 12th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Roth Capital initiated coverage on Stemline Therapeutics in a report on Tuesday, June 12th. They set a “buy” rating and a $30.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Stemline Therapeutics has an average rating of “Buy” and an average target price of $30.00.
Stemline Therapeutics traded down $0.10, reaching $16.60, during midday trading on Thursday, according to Marketbeat.com. 184,000 shares of the company were exchanged, compared to its average volume of 290,805. Stemline Therapeutics has a one year low of $7.30 and a one year high of $20.55. The stock has a market cap of $504.06 million, a P/E ratio of -5.63 and a beta of 0.22.
Several large investors have recently added to or reduced their stakes in STML. Schwab Charles Investment Management Inc. increased its position in shares of Stemline Therapeutics by 17.0% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 47,025 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 6,825 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Stemline Therapeutics during the 4th quarter worth approximately $189,000. Bank of New York Mellon Corp increased its position in shares of Stemline Therapeutics by 23.1% during the 4th quarter. Bank of New York Mellon Corp now owns 100,813 shares of the biopharmaceutical company’s stock worth $1,573,000 after purchasing an additional 18,899 shares during the last quarter. BlackRock Inc. increased its position in shares of Stemline Therapeutics by 6.3% during the 4th quarter. BlackRock Inc. now owns 1,406,181 shares of the biopharmaceutical company’s stock worth $21,936,000 after purchasing an additional 83,044 shares during the last quarter. Finally, Royce & Associates LP acquired a new position in shares of Stemline Therapeutics during the 4th quarter worth approximately $106,000. Institutional investors and hedge funds own 66.91% of the company’s stock.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Get a free copy of the Zacks research report on Stemline Therapeutics (STML)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment